NO991839D0 - FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer - Google Patents

FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer

Info

Publication number: NO991839D0
Authority: NO; Norway
Prior art keywords: alfa; interferon; preparations; expression; delivery
Prior art date: 1996-10-18

Application number

NO991839A

Other languages

English (en)

Other versions

NO991839L (no

Inventor

Tattanahalli L Nagabhushan

Deba P Saha

Original Assignee

Canji Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-18

Filing date

1999-04-16

Publication date

1999-04-16

1999-04-16 Application filed by Canji Inc filed Critical Canji Inc

1999-04-16 Publication of NO991839D0 publication Critical patent/NO991839D0/no

1999-06-15 Publication of NO991839L publication Critical patent/NO991839L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Virology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

NO991839A 1996-10-18 1999-04-16 FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer NO991839L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73381596A	1996-10-18	1996-10-18
PCT/US1997/017928 WO1998017801A1 (en)	1996-10-18	1997-10-16	METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-α NUCLEIC ACIDS

Publications (2)

Publication Number	Publication Date
NO991839D0 true NO991839D0 (no)	1999-04-16
NO991839L NO991839L (no)	1999-06-15

Family

ID=24949214

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO991839A NO991839L (no)	1996-10-18	1999-04-16	FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer

Country Status (20)

Country	Link
EP (2)	EP0932679A1 (no)
JP (2)	JP2001502540A (no)
KR (1)	KR20000049243A (no)
AR (1)	AR013618A1 (no)
AU (1)	AU4808097A (no)
BR (1)	BR9712362A (no)
CA (1)	CA2269100A1 (no)
CZ (1)	CZ131699A3 (no)
DE (1)	DE932679T1 (no)
ES (1)	ES2136583T1 (no)
HU (1)	HUP9904219A2 (no)
ID (1)	ID24500A (no)
IL (1)	IL129387A0 (no)
NO (1)	NO991839L (no)
NZ (1)	NZ335134A (no)
PL (1)	PL332856A1 (no)
SK (1)	SK50699A3 (no)
TR (1)	TR199901190T2 (no)
WO (1)	WO1998017801A1 (no)
ZA (1)	ZA979295B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9912925D0 (en) *	1999-06-03	1999-08-04	Angeletti P Ist Richerche Bio	Adenoviral vectors encoding interferon and their use in gene therapy
US8058248B2 (en) *	2001-04-26	2011-11-15	The United States Of America As Represented By The Secretary Of Agriculture	Foot and mouth disease virus vaccine comprising interferons
NZ536475A (en)	2002-05-24	2008-06-30	Schering Corp	Neutralizing human anti-igfr antibody
US7326567B2 (en)	2003-11-12	2008-02-05	Schering Corporation	Plasmid system for multigene expression
AR046639A1 (es)	2003-11-21	2005-12-14	Schering Corp	Combinaciones terapeuticas de anticuerpo anti- igfr1
CA2548100C (en)	2003-12-10	2015-03-24	Canji, Inc.	Methods and compositions for treatment of interferon-resistant tumors
US7811562B2 (en)	2004-12-03	2010-10-12	Schering Corporation	Biomarkers for pre-selection of patients for anti-IGF1R therapy
AU2007294858B2 (en)	2006-09-14	2011-05-12	Medgenics Medical Israel, Ltd	Long lasting drug formulations
US8454948B2 (en)	2006-09-14	2013-06-04	Medgenics Medical Israel Ltd.	Long lasting drug formulations
EP2626078A1 (en) *	2007-02-23	2013-08-14	Her Majesty The Queen, In Right Of Canada, As Represented by the Minister of National Defence	Inoculation of recombinant viral vectors for rapid pre-exposure prevention and post-exposure protection against alphavirus-induced encephalitides
EP2440251A4 (en) *	2009-06-09	2013-01-16	Defyrus Inc	INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
KR101591887B1 (ko)	2010-06-15	2016-02-04	메드제닉스 메디칼 이스라엘 리미티드	장기 지속형 약물 제형
US20200038487A1 (en)	2017-03-31	2020-02-06	Accanis Biotech F&E Gmbh & Co Kg	Prevention and treatment of non-melanoma skin cancer (nmsc)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4238778C2 (de) *	1992-11-12	1995-11-02	Max Delbrueck Centrum	Vektor zur Expression von therapeutisch relevanten Genen
US5631236A (en) *	1993-08-26	1997-05-20	Baylor College Of Medicine	Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
ATE314482T1 (de) *	1993-10-25	2006-01-15	Canji Inc	Rekombinante adenoviren-vektor und verfahren zur verwendung
US5830686A (en) *	1994-01-13	1998-11-03	Calydon	Tissue-specific enhancer active in prostate
DE4407859C1 (de) *	1994-03-04	1995-03-02	Max Planck Gesellschaft	Vektor für die leberspezifische Gentherapie
JP4216350B2 (ja) *	1994-09-19	2009-01-28	大日本住友製薬株式会社	動物細胞感染用の組換えｄｎａウイルスベクター
US5789244A (en) *	1996-01-08	1998-08-04	Canji, Inc.	Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

1997
- 1997-10-16 HU HU9904219A patent/HUP9904219A2/hu unknown
- 1997-10-16 NZ NZ335134A patent/NZ335134A/en unknown
- 1997-10-16 DE DE0932679T patent/DE932679T1/de active Pending
- 1997-10-16 EP EP97910794A patent/EP0932679A1/en not_active Ceased
- 1997-10-16 TR TR1999/01190T patent/TR199901190T2/xx unknown
- 1997-10-16 CZ CZ991316A patent/CZ131699A3/cs unknown
- 1997-10-16 ES ES97910794T patent/ES2136583T1/es active Pending
- 1997-10-16 JP JP10519400A patent/JP2001502540A/ja not_active Withdrawn
- 1997-10-16 ZA ZA9709295A patent/ZA979295B/xx unknown
- 1997-10-16 IL IL12938797A patent/IL129387A0/xx unknown
- 1997-10-16 ID IDW990218D patent/ID24500A/id unknown
- 1997-10-16 EP EP05013342A patent/EP1591528A3/en not_active Withdrawn
- 1997-10-16 PL PL97332856A patent/PL332856A1/xx unknown
- 1997-10-16 BR BR9712362-5A patent/BR9712362A/pt not_active Application Discontinuation
- 1997-10-16 SK SK506-99A patent/SK50699A3/sk unknown
- 1997-10-16 KR KR1019990703347A patent/KR20000049243A/ko not_active Application Discontinuation
- 1997-10-16 AU AU48080/97A patent/AU4808097A/en not_active Abandoned
- 1997-10-16 WO PCT/US1997/017928 patent/WO1998017801A1/en not_active Application Discontinuation
- 1997-10-16 CA CA002269100A patent/CA2269100A1/en not_active Abandoned
- 1997-10-17 AR ARP970104830A patent/AR013618A1/es not_active Application Discontinuation
1999
- 1999-04-16 NO NO991839A patent/NO991839L/no not_active Application Discontinuation
2008
- 2008-08-20 JP JP2008212260A patent/JP2008301832A/ja active Pending

Also Published As

Publication number	Publication date
EP0932679A1 (en)	1999-08-04
NO991839L (no)	1999-06-15
KR20000049243A (ko)	2000-07-25
IL129387A0 (en)	2000-02-17
ID24500A (id)	2000-07-20
HUP9904219A2 (hu)	2000-12-28
WO1998017801A1 (en)	1998-04-30
TR199901190T2 (xx)	1999-07-21
ZA979295B (en)	1998-04-20
NZ335134A (en)	2001-05-25
AR013618A1 (es)	2001-01-10
DE932679T1 (de)	2000-03-09
AU4808097A (en)	1998-05-15
PL332856A1 (en)	1999-10-25
EP1591528A3 (en)	2005-11-16
CA2269100A1 (en)	1998-04-30
ES2136583T1 (es)	1999-12-01
EP1591528A2 (en)	2005-11-02
SK50699A3 (en)	2000-05-16
JP2001502540A (ja)	2001-02-27
JP2008301832A (ja)	2008-12-18
CZ131699A3 (cs)	1999-07-14
BR9712362A (pt)	1999-08-31

Publication	Publication Date	Title
NO943344D0 (no)	1994-09-09	MN-gen og -protein
FI942935A0 (fi)	1994-06-17	Peptidien nukleiinihappoja ja niiden vaikutus geneettiseen materiaaliin
GB9618050D0 (en)	1996-10-09	Global amplification of nucleic acids
ZA987257B (en)	1999-02-15	Amplification of nucleic acids
HUP9801207A3 (en)	2000-12-28	Therapeutic compositions for transfecting nucleic acids and use thereof
NO972781D0 (no)	1997-06-16	Aerosolformuleringer av peptider og proteiner
PL336889A1 (en)	2000-07-17	Preparations of activated protein c
NO983096L (no)	1998-09-04	Sammensetning og fremgangsmÕte for levering av nukleinsyrer
EP0704532A3 (en)	1996-07-03	Recombinant chimeric proteins and methods of using them
EP0948651A4 (en)	2004-04-07	RECOMBINANT N-SMASES AND CODING NUCLEIC ACIDS
NO991839D0 (no)	1999-04-16	FremgangsmÕter og preparater for utlevering og ekspresjon av interferon-<alfa>-nukleinsyrer
EP0693931A4 (en)	1998-11-18	IMMUNOGENIC PROTEINS AND PEPTIDES OF CANCER AND METHOD OF USE
AU5195398A (en)	1998-05-15	Dna sequences encoding fusions of dna repair proteins and uses thereof
GB9609213D0 (en)	1996-07-03	Amplification of nucleic acids
AU1870597A (en)	1997-07-17	Nucleic acid sequences of genes of the high mobility group proteins and uses thereof
PL333943A1 (en)	2000-01-31	Sequences of nucleic and amino acids associated with heliobacter pylori and vaccines containing such sequences
DK0925273T3 (da)	2002-02-18	Farmaceutiske præparater indeholdende 4-oxo-butansyrer
ZA894800B (en)	1990-05-30	Proteins and nucleic acids
GB9023149D0 (en)	1990-12-05	Proteins and nucleic acids
PL320084A1 (en)	1997-09-15	Nucleic acids of amino acid type
AU8168898A (en)	1999-01-19	Interferon stimulating protein and uses thereof
IL138804A0 (en)	2001-10-31	Hepatitis c virus ns5b nucleic acids and proteins
IL136988A0 (en)	2001-06-14	Novel nucleic acid and polypeptide
EP1220896A4 (en)	2003-04-16	NEW HUMANE LIPASE PROTEINS, FOR CODING NUCLEIC ACIDS AND THEIR USE
AU7637796A (en)	1998-07-03	Expression of active interferon beta 1 using recombinant rna replicons

Legal Events

Date	Code	Title	Description
2002-07-01	FC2A	Withdrawal, rejection or dismissal of laid open patent application